Clinical Trial Update: Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the efficacy, safety and tolerability of AZD6234 in adults with obesity and type 2 diabetes who are on a stable GLP-1 recept…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• AZD6234

Snippet

Sponsor: AstraZeneca | Conditions: Endocrinology, Diabetes, Type II | Phase 2 | Status: ACTIVE_NOT_RECRUITING